Company Analysis

Jaguar Health, Inc. (JAGX)

Nasdaq: JAGX · Pharmaceutical Preparations · San Francisco, CA · filing with the SEC since 2013
Grade3.9
◀ Past 2.9● Present 4.4▶ Future 4.0
1 est.

Income statement, as filed

In US dollars (USD), as filed; per-share figures in US dollars; share counts. The fiscal year ends in December.
Income statement, by fiscal year, newest first
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Period endingDec 31, 2025Dec 31, 2024Dec 31, 2023Dec 31, 2022Dec 31, 2021Dec 31, 2020Dec 31, 2019Dec 31, 2018Dec 31, 2017Dec 31, 2016
Report filedApr 7, 2026Mar 31, 2025Apr 1, 2024Mar 24, 2023Mar 11, 2022Mar 31, 2021Apr 3, 2020Apr 10, 2019Apr 9, 2018Feb 15, 2017
Revenue11,511,00011,689,0009,761,00011,956,0004,335,0009,385,0005,775,000r4,416,1454,361,186141,523
Cost of revenue3,774,0001,955,0002,037,0002,019,0002,333,0003,280,0003,816,000r2,765,746880,40551,966
Research and development24,966,00016,542,00018,596,00017,647,00015,079,0006,413,0005,820,000r5,154,7484,269,4557,206,864
Sales and marketing9,235,0007,692,0006,460,0008,837,0008,894,0006,609,0006,936,000r9,831,5763,083,739485,440
General and administrative18,644,00016,331,00016,588,00017,868,00017,103,00014,387,00013,502,000r12,277,22211,247,6475,983,238
Total operating expenses·······35,240,11338,608,24613,727,508
Total costs and expenses57,419,00042,520,00044,052,00046,371,00045,043,00036,032,00034,723,000r35,240,113··
Operating income-45,908,000-30,831,000-34,291,000-34,415,000-40,708,000-26,647,000-28,948,000r-30,823,968-34,247,060-13,585,985
Interest expense67,000231,0006,382,00012,723,0008,421,0002,792,0005,731,000r2,628,6851,209,632985,549
Share of profit of equity-method investments-162,000-138,000-51,000·······
Other income (expense), net43,00051,000200,000950,000-765,000190,00081,000r315,69188,549-11,046
Income before income taxes-53,997,000-39,251,000-41,901,000-48,395,000-52,600,000-33,809,000-38,529,000r-32,146,057-35,149,856-14,733,780
Income tax expense00000010,000·-13,181,242·
Net income including non-controlling interests-53,997,000-39,251,000-41,901,000-48,395,000-52,600,000-33,809,000-38,539,000r-32,146,057-21,968,614-14,733,780
Net income to non-controlling interests-563,000-759,000-601,000-941,000-5,000·····
Net income-53,575,000-38,492,000-41,900r-48,400r-52,600-33,809,000-38,539,000r-32,146,057-21,968,614-14,733,780
Preferred dividends141,0000········
Net income to common shareholders-53,575,000-38,492,000-41,300,000-47,454,000-52,595,000-38,648,000·-32,146,057-21,968,614-14,733,780
Earnings per share, basic-22.97-130.69-2,678.17r-54,125.28b-131,977.12rb-336,600.00b····
Earnings per share, diluted-22.97-130.69-2,678.17r-54,125.28b-88.22r-336,600.00b····
Earnings per share, basic and diluted·····-112,200.00b-1,010,922.00b-17,196,894.00rb-851,598.00rb-151,470.00b
Weighted average shares, basic2,332,401294,53415,421r877b398rb115b····
Weighted average shares, diluted2,332,401294,53415,421r1,311,519398rb115b····
Weighted average shares, basic and diluted·····344b44b2rb26rb98b
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.Share counts and per-share figures are on the newest report's basis, after the 1-for-1496 reverse split.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Revenue what customers paid for what it soldus-gaap:Revenues
Cost of revenue what it cost to make or buy what it soldus-gaap:CostOfRevenue
Research and development spent on inventing what it sells nextus-gaap:ResearchAndDevelopmentExpense
Sales and marketing the cost of finding and serving customersus-gaap:SellingAndMarketingExpense
General and administrative the cost of running the company itselfus-gaap:GeneralAndAdministrativeExpense
Total operating expenses the running costs togetherus-gaap:OperatingExpenses
Total costs and expenses every operating cost, the cost of revenue includedus-gaap:CostsAndExpenses
Operating income profit from running the business, before interest and taxus-gaap:OperatingIncomeLoss
Interest expense what its borrowing costus-gaap:InterestExpense
Share of profit of equity-method investments its share of companies it partly ownsus-gaap:IncomeLossFromEquityMethodInvestments
Other income (expense), net gains and costs outside the businessus-gaap:OtherNonoperatingIncomeExpense
Income before income taxes profit before taxus-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
Income tax expense tax charged on the period's profitus-gaap:IncomeTaxExpenseBenefit
Net income including non-controlling interests the whole group's profit, minority holders' share includedus-gaap:ProfitLoss
Net income to non-controlling interests the share that belongs to minority holdersus-gaap:NetIncomeLossAttributableToNoncontrollingInterest
Net income the profit or loss that belongs to the company's shareholdersus-gaap:NetIncomeLoss
Preferred dividends paid to preferred holders before common shareholdersus-gaap:PreferredStockDividendsIncomeStatementImpact
Net income to common shareholders what is left for common shareholdersus-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
Earnings per share, basic net income per share outstandingus-gaap:EarningsPerShareBasic
Earnings per share, diluted net income per share, counting every share that could be issuedus-gaap:EarningsPerShareDiluted
Earnings per share, basic and diluted net income per share, where both counts are the sameus-gaap:EarningsPerShareBasicAndDiluted
Weighted average shares, basic the average count of shares outstandingus-gaap:WeightedAverageNumberOfSharesOutstandingBasic
Weighted average shares, diluted the average count with every share that could be issuedus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Weighted average shares, basic and diluted the average count, where both counts are the sameus-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
SI Assistanton JAGX · research, not advice